ストックスクリーナーアプリを入手
2.39
8.08%
-0.21
前日終値:
$2.60
開ける：
$2.6
24時間の取引高:
197.13K
Relative Volume:
0.67
時価総額：
$243.24M
収益：
$4.60M
当期純損益:
$-82.31M
株価収益率:
-2.9139
EPS:
-0.8202
ネットキャッシュフロー:
$-87.79M
1週間 パフォーマンス:
-4.78%
1か月 パフォーマンス:
+12.74%
6か月 パフォーマンス:
-29.91%
1年 パフォーマンス:
+13.27%
1日の値動き範囲:
$2.39
$2.60
1週間の範囲:
$2.39
$2.6301
52週間の値動き範囲:
$2.00
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.39 | 243.24M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | BTIG Research | Buy |
| 2019-02-01 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-04 | 開始されました | UBS | Buy |
| 2018-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-23 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 開始されました | Credit Suisse | Outperform |
| 2016-10-18 | 開始されました | Jefferies | Buy |
| 2016-10-18 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Ac Immune Sa (ACIU) 最新ニュース
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - The Manila Times
AC Immune brings three neurodegeneration studies to AAIC 2026 - Stock Titan
AC Immune: Holding Into A Make-Or-Break H2 2026 Readout (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
Price to earnings forward of AC Immune SA – DUS:IMR - TradingView
Price to sales forward of AC Immune SA – NASDAQ:ACIU - TradingView
AC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program - TipRanks
Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer’s trial update - Stock Titan
ACIU: Promising Interim Results from AC Immune's Alzheimer's Stu - GuruFocus
AC Immune reports interim trial data for Alzheimer’s drug ACI-24 - Investing.com Australia
AC Immune Reports Interim 12-Month ABATE Data for ACI-24 in Prodromal Alzheimer’s Disease - Quiver Quantitative
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease - GlobeNewswire
AC Immune’s Alzheimer’s vaccine shows antibody response in 74 patients - Stock Titan
AC Immune Q1 2026 Earnings: Narrowing Losses and Positive Pipeline MomentumFree Cash Flow Trends - dars.gov.et
Enterprise value to EBITDA forward of AC Immune SA – NASDAQ:ACIU - TradingView
Enterprise value to EBIT forward of AC Immune SA – NASDAQ:ACIU - TradingView
Price to book forward of AC Immune SA – NASDAQ:ACIU - TradingView
Enterprise value to revenue forward of AC Immune SA – NASDAQ:ACIU - TradingView
Price to earnings forward of AC Immune SA – NASDAQ:ACIU - TradingView
ACIU Forecast — Price Target — Prediction for 2027 - TradingView
AC Immune Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesTax Rate Impact - dars.gov.et
AC Immune SA (ACIU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Sparks Modest Stock GainGuidance Downgrade Alert - dars.gov.et
AC Immune SA (ACIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis - TradingKey
AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACIU Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
June 2026 Penny Stocks To Watch For Potential Growth - simplywall.st
AC Immune (ACIU) director receives restricted share units and options grant - Stock Titan
AC Immune (ACIU) director receives new RSU and stock option grants - Stock Titan
AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options - Stock Titan
AC Immune (ACIU) grants RSUs and stock options to director Buetler - Stock Titan
[Form 4] AC Immune SA Insider Trading Activity - Stock Titan
AC Immune Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Investor ResponseDividend Increase Stocks - newsline.com
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM - TipRanks
AC Immune (NASDAQ: ACIU) AGM clears 2025 loss, extends capital band and boosts liquidity runway - Stock Titan
Three Swiss biotech companies secure grants - Startupticker.ch
AC Immune receives $4m grant for Parkinson’s trial extension - Investing.com UK
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial - TipRanks
AC Immune receives $4m grant for Parkinson’s trial extension By Investing.com - Investing.com Canada
AC Immune (NASDAQ: ACIU) awarded $4M grant to extend ACI-7104 PD trial - Stock Titan
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease - GlobeNewswire
AC Immune Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Lift SentimentEPS Growth Report - newsline.com
Ac Immune Sa (ACIU) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):